Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer

被引：0
|
作者：
Koichi Uemura
Yasuhide Miyoshi
Takashi Kawahara
Shuko Yoneyama
Yusuke Hattori
Jun-ichi Teranishi
Keiichi Kondo
Masatoshi Moriyama
Shigeo Takebayashi
Yumiko Yokomizo
Masahiro Yao
Hiroji Uemura
Kazumi Noguchi
机构：
[1] Yokohama City University Medical Center,Department of Urology and Renal Transplantation
[2] Yokohama Municipal Citizen’s Hospital,Department of Urology
[3] Yokohama City University Medical Center,Department of Radiology
[4] Yokohama City University Graduate School of Medicine,Department of Urology
来源：
BMC Cancer | / 16卷
关键词：
Prostate cancer; Castration-resistant; Survival prediction; Bone scan index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [22] Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy
    Qu, Yuan-Yuan
    Dai, Bo
    Kong, Yun-Yi
    Ye, Ding-Wei
    Yao, Xu-Dong
    Zhang, Shi-Lin
    Zhang, Hai-Liang
    Ma, Chun-Guang
    Yang, Wei-Yi
    ASIAN JOURNAL OF ANDROLOGY, 2013, 15 (01) : 110 - 115
  • [23] Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel
    Ryan, Charles J.
    Dutta, Sandipan
    Kelly, William K.
    Middleberg, Rob
    Russell, Carly
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 222 - +
  • [24] TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL
    Silva Miguel, L.
    Paquete, A. T.
    Guerreiro, R.
    Fiorentino, F.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S71 - S71
  • [25] Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
    Ohtaka, Ayako
    Aoki, Hiroaki
    Nagata, Masayoshi
    Kanayama, Mayuko
    Shimizu, Fumitaka
    Ide, Hisamitsu
    Tsujimura, Akira
    Horie, Shigeo
    PROSTATE INTERNATIONAL, 2019, 7 (01) : 9 - 14
  • [26] Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases
    Miyoshi, Yasuhide
    Yoneyama, Shuko
    Kawahara, Takashi
    Hattori, Yusuke
    Teranishi, Jun-ichi
    Kondo, Keiichi
    Moriyama, Masatoshi
    Takebayashi, Shigeo
    Yokomizo, Yumiko
    Yao, Masahiro
    Uemura, Hiroji
    Noguchi, Kazumi
    BMC CANCER, 2016, 16
  • [27] Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases
    Yasuhide Miyoshi
    Shuko Yoneyama
    Takashi Kawahara
    Yusuke Hattori
    Jun-ichi Teranishi
    Keiichi Kondo
    Masatoshi Moriyama
    Shigeo Takebayashi
    Yumiko Yokomizo
    Masahiro Yao
    Hiroji Uemura
    Kazumi Noguchi
    BMC Cancer, 16
  • [28] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [29] Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer
    Yamada, Yasutaka
    Sakamoto, Shinichi
    Rii, Junryo
    Yamamoto, Satoshi
    Kamada, Shuhei
    Imamura, Yusuke
    Nakamura, Kazuyoshi
    Komiya, Akira
    Nakatsu, Hiroomi
    Ichikawa, Tomohiko
    PROSTATE, 2020, 80 (07): : 559 - 569
  • [30] Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).
    Morgans, Alicia Katherine
    Graves, Amy J.
    Penson, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345